CHRNA5 links chandelier cells to severity of amyloid pathology in aging and Alzheimer’s Disease
Authors:
- Jonas RybnicekJRJonas Rybnicek
- Yuxiao ChenYCYuxiao Chen
- Earvin TioETEarvin Tio
- JoAnne McLaurinJMJoAnne McLaurin
- Timothy J. HohmanTHTimothy J. Hohman
- Philip L De JagerPJPhilip L De Jager
- Shreejoy TripathySTShreejoy Tripathy
- Daniel FelskyDFDaniel Felsky
Preprint
Abstract
Changes in high-affinity nicotinic acetylcholine receptors are intricately connected to neuropathology in Alzheimer’s Disease (AD). Protective and cognitive-enhancing roles for the nicotinic α5 subunit have been identified, but this gene has not been closely examined in the context of human aging and dementia. Therefore, we investigate the nicotinic α5 gene CHRNA5 and the impact of relevant single nucleotide polymorphisms (SNPs) in prefrontal cortex from 922 individuals with matched genotypic and post-mortem RNA sequencing in the Religious Orders Study and Memory and Aging Project (ROS/MAP). We find that a genotype robustly linked to increased expression of CHRNA5 (rs1979905A2) predicts significantly reduced cortical β-amyloid load. Intriguingly, co-expression analysis suggests CHRNA5 has a distinct cellular expression profile compared to other nicotinic receptor genes. Consistent with this prediction, single nucleus RNA sequencing from 22 individuals reveals CHRNA5 expression is disproportionately-elevated in chandelier neurons, a distinct subtype of inhibitory neuron known for its role in excitatory/inhibitory (E/I) balance. We show that chandelier neurons are enriched in amyloid-binding proteins compared to basket cells, the other major subtype of PVALB-positive interneurons. Consistent with the hypothesis that nicotinic receptors in chandelier cells normally protect against β-amyloid, cell-type proportion analysis from 549 individuals reveals these neurons show amyloid-associated vulnerability only in individuals with impaired function/trafficking of nicotinic α5-containing receptors due to homozygosity of the missense CHRNA5 SNP (rs16969968A2). Taken together, these findings suggest that CHRNA5 and its nicotinic α5 subunit exert a neuroprotective role in aging and Alzheimer’s disease centered on chandelier interneurons.Keywords
All Related Versions
- Published version: Translational Psychiatry, 14 (1), 1.
This publication has 86 references indexed in Scilit:
- Neuroinflammation and Neuronal Loss Precede Aβ Plaque Deposition in the hAPP-J20 Mouse Model of Alzheimer’s DiseasePLOS ONE, 2013
- Varenicline for smoking cessation: nausea severity and variation in nicotinic receptor genesThe Pharmacogenomics Journal, 2011
- Acetylcholine Receptor (AChR) α5 Subunit Variant Associated with Risk for Nicotine Dependence and Lung Cancer Reduces (α4β2)2α5 AChR FunctionMolecular Pharmacology, 2011
- Role of α7 Nicotinic Acetylcholine Receptor in Calcium Signaling Induced by Prion Protein Interaction with Stress-inducible Protein 1Journal of Biological Chemistry, 2010
- CHRNB2 promoter region: association with subjective effects to nicotine and gene expression differencesGenes, Brain and Behavior, 2010
- Resequencing of Nicotinic Acetylcholine Receptor Genes and Association of Common and Rare Variants with the Fagerström Test for Nicotine DependenceNeuropsychopharmacology, 2010
- Nicotinic α5 receptor subunit mRNA expression is associated with distant 5′ upstream polymorphismsEuropean Journal of Human Genetics, 2010
- Cellular Prion Protein Mediates the Toxicity of β-Amyloid OligomersArchives of Neurology, 2009
- Nicotinic Acetylcholine Receptor Signalling: Roles in Alzheimer’s Disease and Amyloid NeuroprotectionPharmacological Reviews, 2009
- Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor proteinProceedings of the National Academy of Sciences, 2005